Zinc oxide nanoparticles attenuate hepatic steatosis development in high-fat-diet fed mice through activated AMPK signaling axis
- Resource Type
- Authors
- Prosenjit Mondal; Satyakam Patnaik; Khyati Girdhar; Abhinav Choubey; Debabrata Ghosh; Surbhi Dogra; Aditya K. Kar; P. Vineeth Daniel; Subrata Ghosh; Swarup Chatterjee
- Source
- Nanomedicine: Nanotechnology, Biology and Medicine. 17:210-222
- Subject
- medicine.medical_specialty
Biomedical Engineering
Enzyme Activators
Pharmaceutical Science
Medicine (miscellaneous)
chemistry.chemical_element
Bioengineering
02 engineering and technology
Zinc
AMP-Activated Protein Kinases
Diet, High-Fat
03 medical and health sciences
Insulin resistance
Non-alcoholic Fatty Liver Disease
In vivo
Internal medicine
medicine
Animals
Humans
General Materials Science
030304 developmental biology
0303 health sciences
Fatty liver
nutritional and metabolic diseases
AMPK
Hep G2 Cells
021001 nanoscience & nanotechnology
medicine.disease
Obesity
Mice, Inbred C57BL
Cytosol
Endocrinology
Liver
chemistry
Nanoparticles
Molecular Medicine
Insulin Resistance
Zinc Oxide
Steatosis
0210 nano-technology
Signal Transduction
- Language
- ISSN
- 1549-9634
Insulin resistance is thought to be a common link between obesity and Non-Alcoholic Fatty Liver Disease (NAFLD). NAFLD has now reached epidemic status worldwide and identification of molecules or pathways as newer therapeutic strategies either to prevent or overcome insulin resistance seems critical. Dysregulated hepatic lipogenesis (DNL) is a hallmark of NAFLD in humans and rodents. Therefore, reducing DNL accretion may be critical in the development of therapeutics of NAFLD. In our in vivo model (high-fat-diet fed [HFD] obese mice) we found Zinc oxide nanoparticles (ZnO NPs) significantly decreased HFD-induced hepatic steatosis and peripheral insulin resistance. This protective mechanism of ZnO NPs was signaled through hepatic SIRT1-LKB1-AMPK which restricted SREBP-1c within the cytosol limiting its transcriptional ability and thereby ameliorating HFD mediated DNL. These observations indicate that ZnO NP can serve as a therapeutic strategy to improve the physiological homeostasis during obesity and its associated metabolic abnormalities.